The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
John S Stadwijk - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of sodium picosulfate magnesium citrate for bowel preparation in a physically disabled outpatient population a randomized endoscopist blinded comparison with ascorbic acid enriched polyethylene Glycol Solution plus bisacodyl the p
Diseases of The Colon & Rectum, 2018Co-Authors: Elisabeth M H Mathusvliegen, Karin Van Der Vliet, Inge Wignandvan Der J Storm, John S StadwijkAbstract:BACKGROUND Because of its volume, adequate bowel preparation remains problematic in physically unfit patients. OBJECTIVE This study aimed to compare a small-volume sodium picosulfate/magnesium citrate preparation with a 2-L ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl. DESIGN This study has a noninferiority design, assuming that ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl is 70% efficacious in achieving an Ottawa score ≤7 and accepting a difference in success rate of <15% with a target enrollment of 146 patients per group. SETTING This study was conducted in an outpatient department. PATIENTS Patients referred for diagnostic colonoscopy were randomly assigned. Key exclusion criteria were severe kidney disease, ASA class ≥III, and hospital admission. INTERVENTION Patients were randomly assigned to receive sodium picosulfate/magnesium citrate or ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl according to a split-dose regimen. Patients in the sodium picosulfate/magnesium citrate group received advice on the recommended 4-L fluid intake. Patients in the ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl group received 2 bisacodyl tablets 2 days before and advice on the additionally recommended 2-L fluid intake. MAIN OUTCOME MEASURES To assess bowel-cleansing adequacy, the Ottawa, Aronchick, and Boston scores were used. Colonoscopy quality measures were obtained. Safety was assessed for a 30-day follow-up period. RESULTS Overall, 341 patients (169 men, mean age 57.0 years; BMI 26.2 kg/m) were included. Comorbidities were present in 76.2% of patients, and 75.4% of patients used medication. An adequate Ottawa score was obtained in 81.4% and 75.8% of patients receiving ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl and sodium picosulfate/magnesium citrate (difference of 5.6% (95% CI, -3.5 to -14.6; p = 0.023)), showing noninferiority of the sodium picosulfate/magnesium citrate therapy. Ottawa segmental scores were lower for sodium picosulfate/magnesium citrate in the right and transverse colon. In both groups, successful ileocecal intubation was achieved in 95%. No medication-related adverse events were reported. LIMITATIONS These results in a physically disabled ambulant population cannot be extrapolated to immobile, hospitalized patients. CONCLUSIONS Sodium picosulfate/magnesium citrate proved to be noninferior to ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl in efficacy and safety. Timing of the colonoscopy and addition of bisacodyl to sodium picosulfate/magnesium citrate warrants further consideration. See Video Abstract at http://links.lww.com/DCR/A461.
-
Efficacy and Safety of Sodium Picosulfate/Magnesium Citrate for Bowel Preparation in a Physically Disabled Outpatient Population: A Randomized, Endoscopist-Blinded Comparison With Ascorbic Acid-Enriched Polyethylene Glycol Solution Plus Bisacodyl (Th
Diseases of The Colon & Rectum, 2018Co-Authors: Elisabeth M. H. Mathus-vliegen, Karin Van Der Vliet, Inge J. Wignand-van Der Storm, John S StadwijkAbstract:BACKGROUND Because of its volume, adequate bowel preparation remains problematic in physically unfit patients. OBJECTIVE This study aimed to compare a small-volume sodium picosulfate/magnesium citrate preparation with a 2-L ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl. DESIGN This study has a noninferiority design, assuming that ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl is 70% efficacious in achieving an Ottawa score ≤7 and accepting a difference in success rate of
-
Efficacy and Safety of Sodium Picosulfate/Magnesium Citrate for Bowel Preparation in a Physically Disabled Outpatient Population: A Randomized, Endoscopist-Blinded Comparison With Ascorbic Acid-Enriched Polyethylene Glycol Solution Plus Bisacodyl (Th
Diseases of the colon and rectum, 2018Co-Authors: Elisabeth M. H. Mathus-vliegen, Karin Van Der Vliet, Inge J. Wignand-van Der Storm, John S StadwijkAbstract:Because of its volume, adequate bowel preparation remains problematic in physically unfit patients. This study aimed to compare a small-volume sodium picosulfate/magnesium citrate preparation with a 2-L ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl. This study has a noninferiority design, assuming that ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl is 70% efficacious in achieving an Ottawa score ≤7 and accepting a difference in success rate of <15% with a target enrollment of 146 patients per group. This study was conducted in an outpatient department. Patients referred for diagnostic colonoscopy were randomly assigned. Key exclusion criteria were severe kidney disease, ASA class ≥III, and hospital admission. Patients were randomly assigned to receive sodium picosulfate/magnesium citrate or ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl according to a split-dose regimen. Patients in the sodium picosulfate/magnesium citrate group received advice on the recommended 4-L fluid intake. Patients in the ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl group received 2 bisacodyl tablets 2 days before and advice on the additionally recommended 2-L fluid intake. To assess bowel-cleansing adequacy, the Ottawa, Aronchick, and Boston scores were used. Colonoscopy quality measures were obtained. Safety was assessed for a 30-day follow-up period. Overall, 341 patients (169 men, mean age 57.0 years; BMI 26.2 kg/m) were included. Comorbidities were present in 76.2% of patients, and 75.4% of patients used medication. An adequate Ottawa score was obtained in 81.4% and 75.8% of patients receiving ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl and sodium picosulfate/magnesium citrate (difference of 5.6% (95% CI, -3.5 to -14.6; p = 0.023)), showing noninferiority of the sodium picosulfate/magnesium citrate therapy. Ottawa segmental scores were lower for sodium picosulfate/magnesium citrate in the right and transverse colon. In both groups, successful ileocecal intubation was achieved in 95%. No medication-related adverse events were reported. These results in a physically disabled ambulant population cannot be extrapolated to immobile, hospitalized patients. Sodium picosulfate/magnesium citrate proved to be noninferior to ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl in efficacy and safety. Timing of the colonoscopy and addition of bisacodyl to sodium picosulfate/magnesium citrate warrants further consideration. See Video Abstract at http://links.lww.com/DCR/A461.
Stephen Vanner - One of the best experts on this subject based on the ideXlab platform.
-
combined low volume polyethylene Glycol Solution plus stimulant laxatives versus standard volume polyethylene Glycol Solution a prospective randomized study of colon cleansing before colonoscopy
Canadian Journal of Gastroenterology & Hepatology, 2006Co-Authors: Lawrence Hookey, William T Depew, Stephen VannerAbstract:INTRODUCTION: The effectiveness of polyethylene Glycol Solutions (PEG) for colon cleansing is often limited by the inability of patients to drink adequate portions of the 4 L Solution. The aim of the present study was to determine whether a reduced volume of PEG combined with stimulant laxatives would be better tolerated and as or more effective than the standard dose.
-
Combined low volume polyethylene Glycol Solution plus stimulant laxatives versus standard volume polyethylene Glycol Solution: a prospective, randomized study of colon cleansing before colonoscopy.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2006Co-Authors: Lawrence Hookey, William T Depew, Stephen VannerAbstract:The effectiveness of polyethylene Glycol Solutions (PEG) for colon cleansing is often limited by the inability of patients to drink adequate portions of the 4 L Solution. The aim of the present study was to determine whether a reduced volume of PEG combined with stimulant laxatives would be better tolerated and as or more effective than the standard dose. Patients undergoing outpatient colonoscopy were randomly assigned to receive either low-volume PEG plus sennosides (120 mg oral sennosides syrup followed by 2 L PEG) or the standard volume preparation (4 L PEG). The subjects rated the tolerability of the preparations and their symptoms. Colonoscopists were blind to the colonic cleansing preparation and graded the cleansing efficacy using a validated tool (the Ottawa scale). The low-volume PEG plus sennosides preparation was significantly better tolerated than the standard large volume PEG (P<0.001) but was less efficacious (P=0.03). Thirty-eight per cent of patients in the large volume PEG group were unable to finish the preparation, compared with only 6% in the reduced volume group. There were no adverse events reported. Although the low-volume PEG plus sennosides preparation was better tolerated, it was not as effective as standard large-volume PEG. However, in view of the significant difference in tolerance, further research investigating possible improvements in the reduced-volume regimen seems warranted.
-
a prospective randomized trial comparing low dose oral sodium phosphate plus stimulant laxatives with large volume polyethylene Glycol Solution for colon cleansing
The American Journal of Gastroenterology, 2004Co-Authors: Lawrence Hookey, William T Depew, Stephen VannerAbstract:A Prospective Randomized Trial Comparing Low-Dose Oral Sodium Phosphate Plus Stimulant Laxatives with Large Volume Polyethylene Glycol Solution for Colon Cleansing
Lawrence Hookey - One of the best experts on this subject based on the ideXlab platform.
-
combined low volume polyethylene Glycol Solution plus stimulant laxatives versus standard volume polyethylene Glycol Solution a prospective randomized study of colon cleansing before colonoscopy
Canadian Journal of Gastroenterology & Hepatology, 2006Co-Authors: Lawrence Hookey, William T Depew, Stephen VannerAbstract:INTRODUCTION: The effectiveness of polyethylene Glycol Solutions (PEG) for colon cleansing is often limited by the inability of patients to drink adequate portions of the 4 L Solution. The aim of the present study was to determine whether a reduced volume of PEG combined with stimulant laxatives would be better tolerated and as or more effective than the standard dose.
-
Combined low volume polyethylene Glycol Solution plus stimulant laxatives versus standard volume polyethylene Glycol Solution: a prospective, randomized study of colon cleansing before colonoscopy.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2006Co-Authors: Lawrence Hookey, William T Depew, Stephen VannerAbstract:The effectiveness of polyethylene Glycol Solutions (PEG) for colon cleansing is often limited by the inability of patients to drink adequate portions of the 4 L Solution. The aim of the present study was to determine whether a reduced volume of PEG combined with stimulant laxatives would be better tolerated and as or more effective than the standard dose. Patients undergoing outpatient colonoscopy were randomly assigned to receive either low-volume PEG plus sennosides (120 mg oral sennosides syrup followed by 2 L PEG) or the standard volume preparation (4 L PEG). The subjects rated the tolerability of the preparations and their symptoms. Colonoscopists were blind to the colonic cleansing preparation and graded the cleansing efficacy using a validated tool (the Ottawa scale). The low-volume PEG plus sennosides preparation was significantly better tolerated than the standard large volume PEG (P<0.001) but was less efficacious (P=0.03). Thirty-eight per cent of patients in the large volume PEG group were unable to finish the preparation, compared with only 6% in the reduced volume group. There were no adverse events reported. Although the low-volume PEG plus sennosides preparation was better tolerated, it was not as effective as standard large-volume PEG. However, in view of the significant difference in tolerance, further research investigating possible improvements in the reduced-volume regimen seems warranted.
-
a prospective randomized trial comparing low dose oral sodium phosphate plus stimulant laxatives with large volume polyethylene Glycol Solution for colon cleansing
The American Journal of Gastroenterology, 2004Co-Authors: Lawrence Hookey, William T Depew, Stephen VannerAbstract:A Prospective Randomized Trial Comparing Low-Dose Oral Sodium Phosphate Plus Stimulant Laxatives with Large Volume Polyethylene Glycol Solution for Colon Cleansing
Bing Zhang - One of the best experts on this subject based on the ideXlab platform.
-
Clinical trial: sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene Glycol Solution plus bisacodyl tablets for bowel preparation.
Alimentary pharmacology & therapeutics, 2007Co-Authors: Gary R Lichtenstein, Nav Grandhi, Sandra Lottes, William P Forbes, Kelli Walker, M. Schmalz, Bing ZhangAbstract:Patient acceptance of bowel preparation can affect colon cancer screening compliance. Aim To compare patient acceptance, preference and tolerability of 32-sodium phosphate tablets vs. 2L polyethylene Glycol Solution plus 4 bisacodyl tablets for bowel preparation. A prospective, randomized, investigator-blinded, multicentre trial was performed. Results were based on responses to a patient questionnaire. 411 patients (205 sodium phosphate; 206 polyethylene Glycol plus bisacodyl) completed the study preparation and patient questionnaire prior to colonoscopy. More patients receiving sodium phosphate vs. polyethylene Glycol plus bisacodyl found it easy to take (77% vs. 42%), reported it to be without taste (47% vs. 6%), found it easy to take with respect to volume of liquid prescribed (72% vs. 27%) and indicated they would take the same preparation again in the future (96% vs. 74%, P < 0.0001 for all). Fewer patients receiving sodium phosphate vs. polyethylene Glycol plus bisacodyl had to take time off work or change ordinary activities to take the study preparation (18% vs. 52%, P < 0.0001). Nausea, vomiting, bloating and abdominal pain were reported less frequently with sodium phosphate (P < 0.0013). The 32-tablet sodium phosphate dosing regimen was easier to take and better tolerated, when compared to 2L polyethylene Glycol plus bisacodyl tablets for bowel preparation.
-
clinical trial sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene Glycol Solution plus bisacodyl tablets for bowel preparation
Alimentary Pharmacology & Therapeutics, 2007Co-Authors: Gary R Lichtenstein, Nav Grandhi, M J Schmalz, Sandra Lottes, William P Forbes, Kelli Walker, Bing ZhangAbstract:Summary Background Patient acceptance of bowel preparation can affect colon cancer screening compliance. Aim To compare patient acceptance, preference and tolerability of 32-sodium phosphate tablets vs. 2L polyethylene Glycol Solution plus 4 bisacodyl tablets for bowel preparation. Methods A prospective, randomized, investigator-blinded, multicentre trial was performed. Results were based on responses to a patient questionnaire. Results 411 patients (205 sodium phosphate; 206 polyethylene Glycol plus bisacodyl) completed the study preparation and patient questionnaire prior to colonoscopy. More patients receiving sodium phosphate vs. polyethylene Glycol plus bisacodyl found it easy to take (77% vs. 42%), reported it to be without taste (47% vs. 6%), found it easy to take with respect to volume of liquid prescribed (72% vs. 27%) and indicated they would take the same preparation again in the future (96% vs. 74%, P < 0.0001 for all). Fewer patients receiving sodium phosphate vs. polyethylene Glycol plus bisacodyl had to take time off work or change ordinary activities to take the study preparation (18% vs. 52%, P < 0.0001). Nausea, vomiting, bloating and abdominal pain were reported less frequently with sodium phosphate (P < 0.0013). Conclusion The 32-tablet sodium phosphate dosing regimen was easier to take and better tolerated, when compared to 2L polyethylene Glycol plus bisacodyl tablets for bowel preparation.
-
A Randomized, Multicenter Study Comparing the Safety and Efficacy of Sodium Phosphate Tablets With 2L Polyethylene Glycol Solution Plus Bisacodyl Tablets for Colon Cleansing
The American journal of gastroenterology, 2007Co-Authors: John F. Johanson, Sandra Lottes, William P Forbes, Kelli Walker, Bing Zhang, John Popp, Lawrence B. Cohen, Edwin Carter, Martin RoseAbstract:A Randomized, Multicenter Study Comparing the Safety and Efficacy of Sodium Phosphate Tablets With 2L Polyethylene Glycol Solution Plus Bisacodyl Tablets for Colon Cleansing
Karin Van Der Vliet - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of sodium picosulfate magnesium citrate for bowel preparation in a physically disabled outpatient population a randomized endoscopist blinded comparison with ascorbic acid enriched polyethylene Glycol Solution plus bisacodyl the p
Diseases of The Colon & Rectum, 2018Co-Authors: Elisabeth M H Mathusvliegen, Karin Van Der Vliet, Inge Wignandvan Der J Storm, John S StadwijkAbstract:BACKGROUND Because of its volume, adequate bowel preparation remains problematic in physically unfit patients. OBJECTIVE This study aimed to compare a small-volume sodium picosulfate/magnesium citrate preparation with a 2-L ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl. DESIGN This study has a noninferiority design, assuming that ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl is 70% efficacious in achieving an Ottawa score ≤7 and accepting a difference in success rate of <15% with a target enrollment of 146 patients per group. SETTING This study was conducted in an outpatient department. PATIENTS Patients referred for diagnostic colonoscopy were randomly assigned. Key exclusion criteria were severe kidney disease, ASA class ≥III, and hospital admission. INTERVENTION Patients were randomly assigned to receive sodium picosulfate/magnesium citrate or ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl according to a split-dose regimen. Patients in the sodium picosulfate/magnesium citrate group received advice on the recommended 4-L fluid intake. Patients in the ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl group received 2 bisacodyl tablets 2 days before and advice on the additionally recommended 2-L fluid intake. MAIN OUTCOME MEASURES To assess bowel-cleansing adequacy, the Ottawa, Aronchick, and Boston scores were used. Colonoscopy quality measures were obtained. Safety was assessed for a 30-day follow-up period. RESULTS Overall, 341 patients (169 men, mean age 57.0 years; BMI 26.2 kg/m) were included. Comorbidities were present in 76.2% of patients, and 75.4% of patients used medication. An adequate Ottawa score was obtained in 81.4% and 75.8% of patients receiving ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl and sodium picosulfate/magnesium citrate (difference of 5.6% (95% CI, -3.5 to -14.6; p = 0.023)), showing noninferiority of the sodium picosulfate/magnesium citrate therapy. Ottawa segmental scores were lower for sodium picosulfate/magnesium citrate in the right and transverse colon. In both groups, successful ileocecal intubation was achieved in 95%. No medication-related adverse events were reported. LIMITATIONS These results in a physically disabled ambulant population cannot be extrapolated to immobile, hospitalized patients. CONCLUSIONS Sodium picosulfate/magnesium citrate proved to be noninferior to ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl in efficacy and safety. Timing of the colonoscopy and addition of bisacodyl to sodium picosulfate/magnesium citrate warrants further consideration. See Video Abstract at http://links.lww.com/DCR/A461.
-
Efficacy and Safety of Sodium Picosulfate/Magnesium Citrate for Bowel Preparation in a Physically Disabled Outpatient Population: A Randomized, Endoscopist-Blinded Comparison With Ascorbic Acid-Enriched Polyethylene Glycol Solution Plus Bisacodyl (Th
Diseases of The Colon & Rectum, 2018Co-Authors: Elisabeth M. H. Mathus-vliegen, Karin Van Der Vliet, Inge J. Wignand-van Der Storm, John S StadwijkAbstract:BACKGROUND Because of its volume, adequate bowel preparation remains problematic in physically unfit patients. OBJECTIVE This study aimed to compare a small-volume sodium picosulfate/magnesium citrate preparation with a 2-L ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl. DESIGN This study has a noninferiority design, assuming that ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl is 70% efficacious in achieving an Ottawa score ≤7 and accepting a difference in success rate of
-
Efficacy and Safety of Sodium Picosulfate/Magnesium Citrate for Bowel Preparation in a Physically Disabled Outpatient Population: A Randomized, Endoscopist-Blinded Comparison With Ascorbic Acid-Enriched Polyethylene Glycol Solution Plus Bisacodyl (Th
Diseases of the colon and rectum, 2018Co-Authors: Elisabeth M. H. Mathus-vliegen, Karin Van Der Vliet, Inge J. Wignand-van Der Storm, John S StadwijkAbstract:Because of its volume, adequate bowel preparation remains problematic in physically unfit patients. This study aimed to compare a small-volume sodium picosulfate/magnesium citrate preparation with a 2-L ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl. This study has a noninferiority design, assuming that ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl is 70% efficacious in achieving an Ottawa score ≤7 and accepting a difference in success rate of <15% with a target enrollment of 146 patients per group. This study was conducted in an outpatient department. Patients referred for diagnostic colonoscopy were randomly assigned. Key exclusion criteria were severe kidney disease, ASA class ≥III, and hospital admission. Patients were randomly assigned to receive sodium picosulfate/magnesium citrate or ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl according to a split-dose regimen. Patients in the sodium picosulfate/magnesium citrate group received advice on the recommended 4-L fluid intake. Patients in the ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl group received 2 bisacodyl tablets 2 days before and advice on the additionally recommended 2-L fluid intake. To assess bowel-cleansing adequacy, the Ottawa, Aronchick, and Boston scores were used. Colonoscopy quality measures were obtained. Safety was assessed for a 30-day follow-up period. Overall, 341 patients (169 men, mean age 57.0 years; BMI 26.2 kg/m) were included. Comorbidities were present in 76.2% of patients, and 75.4% of patients used medication. An adequate Ottawa score was obtained in 81.4% and 75.8% of patients receiving ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl and sodium picosulfate/magnesium citrate (difference of 5.6% (95% CI, -3.5 to -14.6; p = 0.023)), showing noninferiority of the sodium picosulfate/magnesium citrate therapy. Ottawa segmental scores were lower for sodium picosulfate/magnesium citrate in the right and transverse colon. In both groups, successful ileocecal intubation was achieved in 95%. No medication-related adverse events were reported. These results in a physically disabled ambulant population cannot be extrapolated to immobile, hospitalized patients. Sodium picosulfate/magnesium citrate proved to be noninferior to ascorbic acid-enriched polyethylene Glycol Solution plus bisacodyl in efficacy and safety. Timing of the colonoscopy and addition of bisacodyl to sodium picosulfate/magnesium citrate warrants further consideration. See Video Abstract at http://links.lww.com/DCR/A461.